2022-2029年全球體癬藥物市場規模研究和預測，按藥物、給藥途徑、終端用戶、配銷通路和區域分析

體癬是一種影響皮膚上層的真菌感染。可以在身體的任何部位發生或產生，但最常見於腿部和手臂，特別是在無毛的皮膚。體癬，在皮膚上表現為環狀結構。紅毛癬菌、犬小孢子菌和表皮癬菌是引起體癬的真菌。真菌感染發病率的增加和對抗真菌藥物需求的上升是推動市場成長的關鍵因素。

根據美國疾病控制和預防中心（CDC）的估計- 截至2019年，真菌性疾病促使超過75000人住院，每年約有900萬門診病人因真菌性疾病就醫。此外，電子藥店的不斷擴張和全球範圍內不斷成長的醫療保健支出將在預測期內為市場創造有利的成長機會。例如- 根據Statista - 2021年，全球電子製藥市場估計為10億美元，預計到2031年將成長到48億美元。然而，在2022-2029年的整個預測期內，體癬藥物的高成本和嚴格的藥品核准過程阻礙了市場的成長。

全球體癬藥物市場研究的主要地區包括亞太地區、北美、歐洲、拉丁美洲和世界其他地區。由於北美地區皮膚真菌病的發病率不斷上升，以及該地區的醫療保健支出不斷增加，北美地區在收入方面占主導地位。而亞太地區在預測期內預計將以最高的年複合成長率成長，原因是諸如老年病和目標人群的增加，以及該地區領先的市場參與者對新產品開發的投資增加。

該研究的目的是確定近年來不同領域和國家的市場規模，並預測未來幾年的價值。本報告旨在將研究涉及的國家內的產業的定性和定量方面都涵蓋其中。

本報告還提供了關於關鍵方面的詳細資訊，如驅動因素和挑戰，這將確定市場的未來成長。此外，還涵蓋了微觀市場的潛在機會，供利益相關者投資，並詳細分析了競爭格局和主要參與者的產品。

目錄

第一章：執行摘要

• 市場簡介
• 2019-2029年全球及細分市場的估計和預測
  • 2019-2029年，體癬藥物市場，按地區分類
  • 2019-2029年，體癬藥物市場，按藥物分類
  • 2019-2029年，體癬藥物市場，按給藥途徑分類
  • 2019-2029年，體癬藥物市場，按終端用戶分類
  • 2019-2029年，體癬藥物市場，按配銷通路分類
• 主要趨勢
• 估算方法
• 研究假設

第二章：全球大腸癬藥物市場的定義和範圍

• 本研究的目的
• 市場定義和範圍
  • 研究的範圍
  • 產業演變
• 研究涵蓋的年份
• 貨幣兌換率

第三章：全球體癬藥物市場動態

• 體癬藥物市場影響分析（2019-2029年）
  • 市場驅動因素
    • 真菌感染的發病率不斷上升
    • 對抗真菌藥物的需求不斷成長
  • 市場挑戰
    • 體癬藥物的高成本
    • 嚴格的藥物審批程序
  • 市場機會
    • 電子藥店的不斷擴張
    • 全球範圍內不斷成長的醫療開支

第四章：全球體癬藥物市場產業分析

• 波特五力模型
  • 供應商的議價能力
  • 買方的議價能力
  • 新進入者的威脅
  • 替代品的威脅
  • 競爭性的競爭
• 波特五力模型的未來方法（2019-2029年）
• PEST分析
  • 政治因素
  • 經濟
  • 社會
  • 技術
• 最佳投資機會
• 最佳策略
• 產業專家展望
• 分析師建議和結論

第五章：風險評估：COVID-19的影響

• 評估COVID-19對產業的整體影響
• COVID-19前和COVID-19後的市場情況

第六章：按藥物分類的全球肉眼可見的皮膚病藥物市場

• 市場簡介
• 按藥物分類的全球體癬藥物市場，表現- 潛力分析
• 2019-2029年全球體癬藥物市場按藥物分類的估計和預測
• 大腿癬藥物市場，細項分析
  • 抗真菌藥
  • 其他藥物

第7章：全球體癬藥物市場，按給藥途徑分類

• 市場簡介
• 按給藥途徑分類的全球體癬藥物市場，表現- 潛力分析
• 2019-2029年全球體癬藥物市場按給藥途徑的估計和預測
• 大腿癬藥物市場，細項分析
  • 口服
  • 外用
  • 腸外

第八章：按終端用戶分類的全球體癬藥物市場

• 市場簡介
• 按終端用戶分類的全球體癬藥物市場，表現- 潛力分析
• 2019-2029年全球體癬藥物市場按終端用戶的估計和預測
• 大腸癬藥物市場，細項分析
  • 醫院
  • 家庭護理
  • 專業診所

第九章：全球大腸癬藥物市場，按配銷通路分類

• 市場簡介
• 按配銷通路分類的全球體癬藥物市場，表現- 潛力分析
• 2019-2029年全球體癬藥物市場按配銷通路的估計和預測
• 大腿癬藥物市場，細項分析
  • 醫院藥店
  • 網上藥店
  • 零售藥店

第十章：全球體癬藥物市場，區域分析

• 大腿癬藥物市場，區域市場簡介
• 北美洲
  • 美國
    • 2019-2029年，藥物細分的估計和預測
    • 2019-2029年，給藥途徑的細分估計和預測
    • 2019-2029年，終端用戶細分估計和預測
    • 2019-2029年，配銷通路分類估計和預測
  • 加拿大
• 歐洲肉毒桿菌藥物市場簡介
  • 英國
  • 德國
  • 法國
  • 西班牙
  • 義大利
  • 歐洲其他地區
• 亞太地區體癬藥物市場簡況
  • 中國
  • 中國
  • 日本
  • 澳洲
  • 韓國
  • 亞太其他地區
• 拉丁美洲體癬藥物市場概況
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 世界其他地區

第十一章：競爭情報

• 頂級市場戰略
• 公司簡介
  • Novartis AG (Switzerland)
    • 關鍵資訊
    • 縱覽
    • 財務（取決於資料的可用性）
    • 產品摘要
    • 最近的發展情況
  • Endo International Inc (Ireland)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Glenmark Pharmaceuticals Ltd (India)
  • Cipla Inc (India)
  • Dr Reddy's Laboratories Ltd (India)
  • Abbott (US)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Pfizer Inc (US)
  • Zydus Group (India)

第十二章：研究過程

• 研究過程
  • 資料探勘
  • 分析
  • 市場評估
  • 驗證
  • 出版
• 研究屬性
• 研究假設

Global Tinea Corporis Drugs Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Tinea corporis is a fungal infection that affects the upper layer of the skin. It can occur or be produced in any part of the body, but it is most commonly found on the legs and arms, particularly in the glabrous skin. Tinea corporis, also known as ringworm, appears on the skin as a ring structure. Trichophyton rubrum, Microsporum canis, and Epidermophyton floccosum are the fungi that cause tinea corporis. The increasing incidence of fungal infections and rising demand for antifungal drugs are key factors driving the market growth.

As per Centers for Disease Control & Prevention (CDC) estimates - as of 2019, fungal diseases resulted in more than 75,000 hospitalizations and around 9 million outpatient visits occur every year for fungal diseases. Also, rising expansion of e-pharmacies and growing healthcare spending worldwide would create lucrative growth opportunities for the market over the projected period. For instance - as per Statista - In 2021, the global e-pharma market was estimated at USD 1 billion, and it is projected to grow to USD 4.8 billion by the year 2031. However, high cost of Tinea Corporis Drugs and stringent drug approval process hinder the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Tinea Corporis Drugs Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the increasing incidence of fungal diseases of skin as well as rising healthcare spending in the region. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, and increasing investment towards new product development from leading market players in the region.

Major market players included in this report are:

• Novartis AG (Switzerland)
• Endo International Inc (Ireland)
• Teva Pharmaceutical Industries Ltd (Israel)
• Glenmark Pharmaceuticals Ltd (India)
• Cipla Inc (India)
• Dr Reddy's Laboratories Ltd (India)
• Abbott (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Pfizer Inc (U.S.)
• Zydus Group (India)

Recent Developments in the Market:

• On May 16, 2022 - Shionogi & Co., Ltd. and F2G Ltd. Entered into a strategic collaboration to develop and commercialize the new antifungal agent olorofim for invasive fungal infections in European and Asian markets. This new agent Olorofim is a novel oral antifungal therapy developed by F2G to treat invasive aspergillosis (IA) and other rare mold infections.

Global Tinea Corporis Drugs Market Report Scope:

• Historical Data: 2019-2020-2021
• Base Year for Estimation: 2021
• Forecast period: 2022-2029
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Drugs, Route of Administration, End-Users, Distribution Channel, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Drugs

• Anti-Fungal
• Others

By Route of Administration

• Oral
• Topical
• Parenteral

By End-Users

• Hospitals
• Homecare
• Specialty Clinics

By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Rest of the World

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
  • 1.2.1. Tinea Corporis Drugs Market, by Region, 2019-2029 (USD Billion)
  • 1.2.2. Tinea Corporis Drugs Market, by Drugs, 2019-2029 (USD Billion)
  • 1.2.3. Tinea Corporis Drugs Market, by Route of Administration, 2019-2029 (USD Billion)
  • 1.2.4. Tinea Corporis Drugs Market, by End-Users, 2019-2029 (USD Billion)
  • 1.2.5. Tinea Corporis Drugs Market, by Distribution Channel, 2019-2029 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Tinea Corporis Drugs Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Scope of the Study
  • 2.2.2. Industry Evolution
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Tinea Corporis Drugs Market Dynamics

• 3.1. Tinea Corporis Drugs Market Impact Analysis (2019-2029)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Increasing incidence of fungal infections
    • 3.1.1.2. Growing demand for antifungal drugs
  • 3.1.2. Market Challenges
    • 3.1.2.1. High Cost of Tinea Corporis Drugs
    • 3.1.2.2. Stringent drug approval process
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Rising expansion of e-pharmacies
    • 3.1.3.2. Growing healthcare spending worldwide

Chapter 4. Global Tinea Corporis Drugs Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. Industry Experts Prospective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

• 5.1. Assessment of the overall impact of COVID-19 on the industry
• 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Tinea Corporis Drugs Market, by Drugs

• 6.1. Market Snapshot
• 6.2. Global Tinea Corporis Drugs Market by Drugs, Performance - Potential Analysis
• 6.3. Global Tinea Corporis Drugs Market Estimates & Forecasts by Drugs 2019-2029 (USD Billion)
• 6.4. Tinea Corporis Drugs Market, Sub Segment Analysis
  • 6.4.1. Antifungal
  • 6.4.2. Others

Chapter 7. Global Tinea Corporis Drugs Market, by Route of Administration

• 7.1. Market Snapshot
• 7.2. Global Tinea Corporis Drugs Market by Route of Administration, Performance - Potential Analysis
• 7.3. Global Tinea Corporis Drugs Market Estimates & Forecasts by Route of Administration 2019-2029 (USD Billion)
• 7.4. Tinea Corporis Drugs Market, Sub Segment Analysis
  • 7.4.1. Oral
  • 7.4.2. Topical
  • 7.4.3. Parenteral

Chapter 8. Global Tinea Corporis Drugs Market, by End-Users

• 8.1. Market Snapshot
• 8.2. Global Tinea Corporis Drugs Market by End-Users, Performance - Potential Analysis
• 8.3. Global Tinea Corporis Drugs Market Estimates & Forecasts by End-Users 2019-2029 (USD Billion)
• 8.4. Tinea Corporis Drugs Market, Sub Segment Analysis
  • 8.4.1. Hospitals
  • 8.4.2. Homecare
  • 8.4.3. Specialty Clinics

Chapter 9. Global Tinea Corporis Drugs Market, by Distribution Channel

• 9.1. Market Snapshot
• 9.2. Global Tinea Corporis Drugs Market by Distribution Channel, Performance - Potential Analysis
• 9.3. Global Tinea Corporis Drugs Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
• 9.4. Tinea Corporis Drugs Market, Sub Segment Analysis
  • 9.4.1. Hospital Pharmacy
  • 9.4.2. Online Pharmacy
  • 9.4.3. Retail Pharmacy

Chapter 10. Global Tinea Corporis Drugs Market, Regional Analysis

• 10.1. Tinea Corporis Drugs Market, Regional Market Snapshot
• 10.2. North America Tinea Corporis Drugs Market
  • 10.2.1. U.S. Tinea Corporis Drugs Market
    • 10.2.1.1. Drugs breakdown estimates & forecasts, 2019-2029
    • 10.2.1.2. Route of Administration breakdown estimates & forecasts, 2019-2029
    • 10.2.1.3. End-Users breakdown estimates & forecasts, 2019-2029
    • 10.2.1.4. Distribution Channel breakdown estimates & forecasts, 2019-2029
  • 10.2.2. Canada Tinea Corporis Drugs Market
• 10.3. Europe Tinea Corporis Drugs Market Snapshot
  • 10.3.1. U.K. Tinea Corporis Drugs Market
  • 10.3.2. Germany Tinea Corporis Drugs Market
  • 10.3.3. France Tinea Corporis Drugs Market
  • 10.3.4. Spain Tinea Corporis Drugs Market
  • 10.3.5. Italy Tinea Corporis Drugs Market
  • 10.3.6. Rest of Europe Tinea Corporis Drugs Market
• 10.4. Asia-Pacific Tinea Corporis Drugs Market Snapshot
  • 10.4.1. China Tinea Corporis Drugs Market
  • 10.4.2. India Tinea Corporis Drugs Market
  • 10.4.3. Japan Tinea Corporis Drugs Market
  • 10.4.4. Australia Tinea Corporis Drugs Market
  • 10.4.5. South Korea Tinea Corporis Drugs Market
  • 10.4.6. Rest of Asia Pacific Tinea Corporis Drugs Market
• 10.5. Latin America Tinea Corporis Drugs Market Snapshot
  • 10.5.1. Brazil Tinea Corporis Drugs Market
  • 10.5.2. Mexico Tinea Corporis Drugs Market
  • 10.5.3. Rest of Latin America Tinea Corporis Drugs Market
• 10.6. Rest of The World Tinea Corporis Drugs Market

Chapter 11. Competitive Intelligence

• 11.1. Top Market Strategies
• 11.2. Company Profiles
  • 11.2.1. Novartis AG (Switzerland)
    • 11.2.1.1. Key Information
    • 11.2.1.2. Overview
    • 11.2.1.3. Financial (Subject to Data Availability)
    • 11.2.1.4. Product Summary
    • 11.2.1.5. Recent Developments
  • 11.2.2. Endo International Inc (Ireland)
  • 11.2.3. Teva Pharmaceutical Industries Ltd (Israel)
  • 11.2.4. Glenmark Pharmaceuticals Ltd (India)
  • 11.2.5. Cipla Inc (India)
  • 11.2.6. Dr Reddy's Laboratories Ltd (India)
  • 11.2.7. Abbott (U.S.)
  • 11.2.8. F. Hoffmann-La Roche Ltd (Switzerland)
  • 11.2.9. Pfizer Inc (U.S.)
  • 11.2.10. Zydus Group (India)

Chapter 12. Research Process

• 12.1. Research Process
  • 12.1.1. Data Mining
  • 12.1.2. Analysis
  • 12.1.3. Market Estimation
  • 12.1.4. Validation
  • 12.1.5. Publishing
• 12.2. Research Attributes
• 12.3. Research Assumption

LIST OF TABLES

• TABLE 1. Global Tinea Corporis Drugs Market, report scope
• TABLE 2. Global Tinea Corporis Drugs Market estimates & forecasts by Region 2019-2029 (USD Billion)
• TABLE 3. Global Tinea Corporis Drugs Market estimates & forecasts by Drugs 2019-2029 (USD Billion)
• TABLE 4. Global Tinea Corporis Drugs Market estimates & forecasts by Route of Administration 2019-2029 (USD Billion)
• TABLE 5. Global Tinea Corporis Drugs Market estimates & forecasts by End-Users 2019-2029 (USD Billion)
• TABLE 6. Global Tinea Corporis Drugs Market estimates & forecasts by Distribution Channel 2019-2029 (USD Billion)
• TABLE 7. Global Tinea Corporis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 8. Global Tinea Corporis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 9. Global Tinea Corporis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 10. Global Tinea Corporis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 11. Global Tinea Corporis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 12. Global Tinea Corporis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 13. Global Tinea Corporis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 14. Global Tinea Corporis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 15. Global Tinea Corporis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 16. Global Tinea Corporis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 17. U.S. Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 18. U.S. Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 19. U.S. Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 20. Canada Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 21. Canada Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 22. Canada Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 23. UK Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 24. UK Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 25. UK Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 26. Germany Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 27. Germany Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 28. Germany Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 29. France Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 30. France Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 31. France Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 32. Italy Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 33. Italy Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 34. Italy Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 35. Spain Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 36. Spain Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 37. Spain Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 38. RoE Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 39. RoE Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 40. RoE Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 41. China Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 42. China Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 43. China Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 44. India Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 45. India Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 46. India Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 47. Japan Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 48. Japan Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 49. Japan Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 50. South Korea Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 51. South Korea Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 52. South Korea Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 53. Australia Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 54. Australia Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 55. Australia Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 56. RoAPAC Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 57. RoAPAC Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 58. RoAPAC Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 59. Brazil Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 60. Brazil Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 61. Brazil Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 62. Mexico Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 63. Mexico Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 64. Mexico Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 65. RoLA Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 66. RoLA Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 67. RoLA Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 68. Row Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 69. Row Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 70. Row Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 71. List of secondary sources, used in the study of global Tinea Corporis Drugs Market
• TABLE 72. List of primary sources, used in the study of global Tinea Corporis Drugs Market
• TABLE 73. Years considered for the study
• TABLE 74. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

• FIG 1. Global Tinea Corporis Drugs Market, research methodology
• FIG 2. Global Tinea Corporis Drugs Market, Market estimation techniques
• FIG 3. Global Market size estimates & forecast methods
• FIG 4. Global Tinea Corporis Drugs Market, key trends 2021
• FIG 5. Global Tinea Corporis Drugs Market, growth prospects 2022-2029
• FIG 6. Global Tinea Corporis Drugs Market, porters 5 force model
• FIG 7. Global Tinea Corporis Drugs Market, pest analysis
• FIG 8. Global Tinea Corporis Drugs Market, value chain analysis
• FIG 9. Global Tinea Corporis Drugs Market by segment, 2019 & 2029 (USD Billion)
• FIG 10. Global Tinea Corporis Drugs Market by segment, 2019 & 2029 (USD Billion)
• FIG 11. Global Tinea Corporis Drugs Market by segment, 2019 & 2029 (USD Billion)
• FIG 12. Global Tinea Corporis Drugs Market by segment, 2019 & 2029 (USD Billion)
• FIG 13. Global Tinea Corporis Drugs Market by segment, 2019 & 2029 (USD Billion)
• FIG 14. Global Tinea Corporis Drugs Market, regional snapshot 2019 & 2029
• FIG 15. North America Tinea Corporis Drugs Market 2019 & 2029 (USD Billion)
• FIG 16. Europe Tinea Corporis Drugs Market 2019 & 2029 (USD Billion)
• FIG 17. Asia Pacific Tinea Corporis Drugs Market 2019 & 2029 (USD Billion)
• FIG 18. Latin America Tinea Corporis Drugs Market 2019 & 2029 (USD Billion)
• FIG 19. Global Tinea Corporis Drugs Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable